Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clément-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N.

J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30654-8. doi: 10.1016/j.jtho.2017.07.023. [Epub ahead of print]

PMID:
28774861
2.

Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).

Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, Hapdey S, Pallardy A, Mahé MA, Lacombe M, Boisselier P, Guillemard S, Olivier P, Beckendorf V, Salem N, Charrier N, Chajon E, Devillers A, Aide N, Danhier S, Denis F, Muratet JP, Martin E, Riedinger AB, Kolesnikov-Gauthier H, Dansin E, Massabeau C, Courbon F, Farcy Jacquet MP, Kotzki PO, Houzard C, Mornex F, Vervueren L, Paumier A, Fernandez P, Salaun M, Dubray B.

J Nucl Med. 2017 Jul;58(7):1045-1053. doi: 10.2967/jnumed.116.188367. Epub 2017 Mar 2.

PMID:
28254869
3.

The impact of antibodies and virtual crossmatching on intestinal transplant outcomes.

Cheng EY, DuBray BJ, Farmer DG.

Curr Opin Organ Transplant. 2017 Apr;22(2):149-154. doi: 10.1097/MOT.0000000000000393.

PMID:
28151807
4.

Liver Transplantation for Alcoholic Hepatitis.

Busuttil RW, DuBray BJ.

Ann Surg. 2017 Jan;265(1):30-31. doi: 10.1097/SLA.0000000000001994. No abstract available.

PMID:
27611611
5.

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.

Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6.

PMID:
27160475
6.

Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of αvβ3 imaging in determining optimal window.

Becker S, Bohn P, Bouyeure-Petit AC, Modzelewski R, Gensanne D, Picquenot JM, Dubray B, Vera P.

Nucl Med Biol. 2015 Dec;42(12):923-30. doi: 10.1016/j.nucmedbio.2015.08.002. Epub 2015 Aug 12.

PMID:
26410810
7.

Robust feature selection to predict tumor treatment outcome.

Mi H, Petitjean C, Dubray B, Vera P, Ruan S.

Artif Intell Med. 2015 Jul;64(3):195-204. doi: 10.1016/j.artmed.2015.07.002. Epub 2015 Aug 14.

PMID:
26303106
8.

High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Calais J, Dubray B, Nkhali L, Thureau S, Lemarignier C, Modzelewski R, Gardin I, Di Fiore F, Michel P, Vera P.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):858-67. doi: 10.1007/s00259-015-3004-y. Epub 2015 Feb 14.

PMID:
25680400
9.

Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.

Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, Vera P.

J Nucl Med. 2015 Feb;56(2):196-203. doi: 10.2967/jnumed.114.144253. Epub 2015 Jan 8.

10.

BH3-only proteins contribute to steatotic liver ischemia-reperfusion injury.

DuBray BJ Jr, Conzen KD, Upadhya GA, Gunter KL, Jia J, Knolhoff BL, Mohanakumar T, Chapman WC, Anderson CD.

J Surg Res. 2015 Apr;194(2):653-8. doi: 10.1016/j.jss.2014.10.024. Epub 2014 Oct 22.

11.

FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.

Nkhali L, Thureau S, Edet-Sanson A, Doyeux K, Benyoucef A, Gardin I, Michel P, Vera P, Dubray B.

Acta Oncol. 2015 Jun;54(6):909-15. doi: 10.3109/0284186X.2014.973062. Epub 2014 Nov 24.

PMID:
25417733
12.

Delineation of small mobile tumours with FDG-PET/CT in comparison to pathology in breast cancer patients.

Hapdey S, Edet-Sanson A, Gouel P, Martin B, Modzelewski R, Baron M, Berghian A, Forestier-Lebreton F, Georgescu D, Picquenot JM, Gardin I, Dubray B, Vera P.

Radiother Oncol. 2014 Sep;112(3):407-12. doi: 10.1016/j.radonc.2014.08.005. Epub 2014 Sep 9.

PMID:
25216573
13.

Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, Michel P, Dubray B, Vera P.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2008-16. doi: 10.1007/s00259-014-2839-y. Epub 2014 Jul 19.

PMID:
25037871
14.

Random forests to predict rectal toxicity following prostate cancer radiation therapy.

Ospina JD, Zhu J, Chira C, Bossi A, Delobel JB, Beckendorf V, Dubray B, Lagrange JL, Correa JC, Simon A, Acosta O, de Crevoisier R.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1024-31. doi: 10.1016/j.ijrobp.2014.04.027. Epub 2014 Jul 8.

PMID:
25035205
15.

Prediction of lung tumor evolution during radiotherapy in individual patients with PET.

Mi H, Petitjean C, Dubray B, Vera P, Ruan S.

IEEE Trans Med Imaging. 2014 Apr;33(4):995-1003. doi: 10.1109/TMI.2014.2301892.

PMID:
24710167
16.

Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer.

Vera P, Dubray B, Palie O, Buvat I, Hapdey S, Modzelewski R, Benyoucef A, Rousseau C, Meyer ME, Bardet S, Gardin I, Fiore FD, Michel P.

EJNMMI Res. 2014 Mar 7;4(1):12. doi: 10.1186/2191-219X-4-12.

17.

FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).

Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, Meyer ME, Jalali K, Bardet S, Lerouge D, Houzard C, Mornex F, Olivier P, Faure G, Rousseau C, Mahé MA, Gomez P, Brenot-Rossi I, Salem N, Dubray B.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1057-65. doi: 10.1007/s00259-014-2687-9. Epub 2014 Feb 22.

PMID:
24562641
18.

[Usefulness of urethral endoprosthesis in the management of urinary retention after brachytherapy for localized prostate cancer].

Kerkeni W, Chahwan C, Lenormand C, Dubray B, Benyoucef A, Pfister C.

Prog Urol. 2014 Mar;24(3):164-6. doi: 10.1016/j.purol.2013.07.013. Epub 2013 Sep 4. French.

PMID:
24560204
19.

Esophagus segmentation from 3D CT data using skeleton prior-based graph cut.

Grosgeorge D, Petitjean C, Dubray B, Ruan S.

Comput Math Methods Med. 2013;2013:547897. doi: 10.1155/2013/547897. Epub 2013 Aug 29.

20.

[Clinical target volume delineation for radiotherapy of the esophagus].

Lazarescu I, Thureau S, Nkhali L, Pradier O, Dubray B.

Cancer Radiother. 2013 Oct;17(5-6):453-60. doi: 10.1016/j.canrad.2013.07.145. Epub 2013 Sep 4. French.

PMID:
24011793

Supplemental Content

Loading ...
Support Center